Abstract
Protein folding in the cell is a complex process with a fine balance between productive and non-productive folding. To modulate, either up-regulating or down-regulating, the level of one specific protein with multiple approaches is possible, including the modulation of catalysed protein folding, the use of chemical and pharmacological chaperones, alteration of natural protein-protein interactions, the regulation of degradative pathways and manipulation of natural control mechanisms, such as the heat shock response and the unfolded protein response. Errors in proteostasis are linked to a wide range of disease states and many examples exist of the successful manipulation of proteostasis for the partial or complete elimination of the disease phenotype, including for many amyloid based diseases such as Parkinsons and Alzheimers as as well as for loss-of-function diseases such as Fabrys and Gauchers diseases. This review takes an overview of the different approaches that can be used to alter proteostasis with an emphasis on peptidomimetic inhibitors and activators of protein folding. It covers the modulators available, their mechanisms of action and potential limitations, including the problems of specificity in altering proteostasis.
Keywords: Proteostasis, protein folding, peptidomimetic, pharmacological chaperone, chemical chaperone, molecular chaperone, degradation
Current Pharmaceutical Design
Title: Modulating Proteostasis: Peptidomimetic Inhibitors and Activators of Protein Folding
Volume: 15 Issue: 21
Author(s): Feras Hatahet and Lloyd W. Ruddock
Affiliation:
Keywords: Proteostasis, protein folding, peptidomimetic, pharmacological chaperone, chemical chaperone, molecular chaperone, degradation
Abstract: Protein folding in the cell is a complex process with a fine balance between productive and non-productive folding. To modulate, either up-regulating or down-regulating, the level of one specific protein with multiple approaches is possible, including the modulation of catalysed protein folding, the use of chemical and pharmacological chaperones, alteration of natural protein-protein interactions, the regulation of degradative pathways and manipulation of natural control mechanisms, such as the heat shock response and the unfolded protein response. Errors in proteostasis are linked to a wide range of disease states and many examples exist of the successful manipulation of proteostasis for the partial or complete elimination of the disease phenotype, including for many amyloid based diseases such as Parkinsons and Alzheimers as as well as for loss-of-function diseases such as Fabrys and Gauchers diseases. This review takes an overview of the different approaches that can be used to alter proteostasis with an emphasis on peptidomimetic inhibitors and activators of protein folding. It covers the modulators available, their mechanisms of action and potential limitations, including the problems of specificity in altering proteostasis.
Export Options
About this article
Cite this article as:
Hatahet Feras and Ruddock W. Lloyd, Modulating Proteostasis: Peptidomimetic Inhibitors and Activators of Protein Folding, Current Pharmaceutical Design 2009; 15 (21) . https://dx.doi.org/10.2174/138161209788682343
DOI https://dx.doi.org/10.2174/138161209788682343 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Molecular Pharmacology of Non-L-type Calcium Channels
Current Pharmaceutical Design Optimization of Cardiac Metabolism in Diabetes Mellitus
Current Pharmaceutical Design Meet Our Editorial Board Member:
Current Neuropharmacology Classical Neurotransmitters and Neuropeptides Involved in Parkinson's Disease: Focus on Anti-Parkinsonian Drugs
Current Drug Therapy Research/Review: Insights into the Mutation-Induced Dysfunction of Arachidonic Acid Metabolism from Modeling of Human CYP2J2
Current Drug Metabolism Mechanism of Organophosphates (Nerve Gases and Pesticides) and Antidotes: Electron Transfer and Oxidative Stress
Current Medicinal Chemistry Amyloid-β Immunotherapy for Alzheimers Disease
CNS & Neurological Disorders - Drug Targets Polymeric Systems as Nanodevices for siRNA Delivery
Current Gene Therapy Role of FAS in HIV Infection
Current HIV Research Meet Our Associate Editor
Current Alzheimer Research Alzheimers Disease and Retinal Neurodegeneration
Current Alzheimer Research Mind-Body Therapies and Osteoarthritis of the Knee
Current Rheumatology Reviews Evaluation of the Effect of α-L-Guluronic Acid (G2013) on COX-1, COX-2 Activity and Gene Expression for Introducing this Drug as a Novel NSAID with Immunomodulatory Property
Recent Patents on Inflammation & Allergy Drug Discovery A Century of Thioxanthones: Through Synthesis and Biological Applications
Current Medicinal Chemistry A Review Study on Prakriti (Body Constitution) Specific Herbal Tea in Diabetes Mellitus
Current Traditional Medicine Biomaterials in Bearing Surface for Total Hip Arthroplasty: State of the Art
Recent Patents on Biomedical Engineering (Discontinued) Identification of a Pathogenic PSEN1 Ala285Val Mutation Associated with Early-Onset Alzheimer’s Disease
Current Alzheimer Research Release Characteristics In Vitro and In Vivo of In Situ Gels for a Novel Peptide Compared with Low-Molecular-Weight Hydrophilic Drug
Current Drug Delivery Remodeling of Proteostasis Upon Transition to Adulthood is Linked to Reproduction Onset
Current Genomics Male and Female Rats Differ in Brain Cannabinoid CB1 Receptor Density and Function and in Behavioural Traits Predisposing to Drug Addiction: Effect of Ovarian Hormones
Current Pharmaceutical Design